COMMUNIQUÉS West-GlobeNewswire

Ever Joint Claims Evaluated: What the Science Says About EverJoint Joint Support Ingredients
18/03/2026
A 2026 company-issued informational report outlining how Ever Joint positions its joint support formula, ingredient-level research context, oxidative stress claims, pricing structure, and what consumers should verify [...]
Tonix Pharmaceuticals to Present at BIO-Europe Spring 2026
18/03/2026
BERKELEY HEIGHTS, N.J., March 18, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial biotechnology company, announced today that Seth [...]
VitalHub Reports Fourth Quarter 2025 Results
18/03/2026
Annual Recurring Revenue (“ARR”)⁽¹⁾ up 35% YoY to $96.1 million Total Revenue up 52% YoY to $31.4 million Adjusted EBITDA⁽¹⁾ up 47% YoY to $7.4 million TORONTO, March 18, 2026 (GLOBE NEWSWIRE) -- Vitalhub Corp. (TSX:VHI [...]
Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results
18/03/2026
Phase 1 APOLLO data update demonstrated encouraging clinical activity with a 66% objective response rate in relapsed non-Hodgkin lymphoma, including 50% complete responses Research published in Nature Medicine [...]
Alvotech Q4 2025 and Full Year 2025 Financial Results
18/03/2026
A supplemental long ‑ form earnings release providing additional operational details and business update for Q4 2025 and the full year is available at: https://investors.alvotech.com/earnings-calendar The supplemental [...]
Extendicare Announces Proposed Changes to Board of Directors
18/03/2026
MARKHAM, Ontario, March 18, 2026 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) today announced that its board of directors (“Board of Directors” or “Board”) has nominated Josh Blair [...]
ImmuCell Appoints Former Elanco Animal Health Board Member Kathy Turner to Board
18/03/2026
PORTLAND, Maine, March 18, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets products to improve calf [...]
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
18/03/2026
FOSTER CITY, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective March 17, 2026, it granted stock options to purchase [...]
Alvotech Q4 2025 and Full Year 2025 Financial Results
18/03/2026
REYKJAVIK, Iceland, March 18, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ US: ALVO, ICELAND: ALVO, STOCKHOLM: ALVO SDB) Financial Highlights A supplemental long ‑ form earnings release providing additional operational [...]
ADR Ratio Change
18/03/2026
March 18, 2026 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) ADR Ratio Change Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative [...]
Heartflow Reports Fourth Quarter and Full Year 2025 Financial Results
18/03/2026
MOUNTAIN VIEW, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today reported financial results for the fourth [...]
Serina Therapeutics Secures up to $30 Million in Private Placement to Advance Registrational Trial of SER-252 for Advanced Parkinson’s Disease
18/03/2026
- First tranche of $15 million expected to close on March 20, 2026; second tranche of up to $15 million available, for up to $30 million in total proceeds from the sale of common stock and pre-funded warrants priced at [...]
XOMA Royalty Declares Quarterly Preferred Stock Dividends
18/03/2026
EMERYVILLE, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA Royalty’s Series A and [...]
4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
18/03/2026
Completed enrollment in 4D-150 4FRONT-1 wet AMD Phase 3 trial within approximately 11 months, ahead of initial projections and reflecting strong interest from investigators and patients; topline data expected in H1 2027 [...]
BioPorto Successfully Completes Preliminary Analysis of U.S. Adult NGAL Cutoff Study; Pre-Submission expected by End of Q1 2026
18/03/2026
March 18, 2026 Announcement no. 03 BioPorto Successfully Completes Preliminary Analysis of U.S. Adult NGAL Cutoff Study; Pre-Submission expected by End of Q1 2026 COPENHAGEN, DENMARK, March 18, 2026 – BioPorto A/S (“ [...]
Red Boost Claims Evaluated: The Male Performance Powder Under Investigation
18/03/2026
A 2026 informational report covering how Red Boost describes its smooth muscle marketing claims, male sexual performance ingredient research context, pricing structure, and what consumers should know before purchasing [...]
Care@Home 4 Life Announces Strategic Partnership with BrightStar Care® to Deliver Nationwide Premium In-Home Care
18/03/2026
BrightStar Care's nurse-led, Joint Commission–accredited care model joins forces with the Care@Home Guarantee™ to ensure seniors can age in the homes they love with the highest standard of support. Miami, Florida, March [...]
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
18/03/2026
SOUTH SAN FRANCISCO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on March 13, 2026 it granted stock options to purchase an aggregate of 8,628 shares of [...]
Dr. Austin Harris Revolutionizes Mental Health and Pain Management with Personalized, Integrative Ketamine Therapy
18/03/2026
SHERMAN OAKS, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Dr. Austin Harris , a board-certified cardiothoracic anesthesiologist and the founder of NeuroRelief Ketamine & Infusion Therapy, is redefining the treatment [...]

Pages